Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Guillaume Baneyx"'
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
Quartiles for pazopanib steady-state early and late Ctrough
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b1218a1e5ffe88fef3eb69d10ac3562
https://doi.org/10.1158/1078-0432.22464756.v1
https://doi.org/10.1158/1078-0432.22464756.v1
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
Baseline patient characteristics and variables used in population PK analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48eb4954ee424c144785e46eb5a9fa6c
https://doi.org/10.1158/1078-0432.22464753
https://doi.org/10.1158/1078-0432.22464753
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
al population PK parameters for pazopanib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53f205afa12ac763976407661056f3df
https://doi.org/10.1158/1078-0432.22464750.v1
https://doi.org/10.1158/1078-0432.22464750.v1
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
Prediction-corrected visual predictive checks of early (A) and late (B) Ctrough in study PROTECT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bc2a606f7728a41d3c494f8481e45d2
https://doi.org/10.1158/1078-0432.22464768.v1
https://doi.org/10.1158/1078-0432.22464768.v1
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
Purpose: PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between pazopanib exposure (Ctrough) and efficacy and safety was evaluated.Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6ed85d00f818640ec94f8566dc9d19
https://doi.org/10.1158/1078-0432.c.6525795.v1
https://doi.org/10.1158/1078-0432.c.6525795.v1
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
List of PROTECT Study investigators
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaa9edbecf2d95be69d1a7474157432
https://doi.org/10.1158/1078-0432.22464762
https://doi.org/10.1158/1078-0432.22464762
Autor:
Robert J. Motzer, Paola Aimone, Hiya Banerjee, Guillaume Baneyx, Mohamed Elmeliegy, Paul Russo, Christian Doehn, Naomi B. Haas, Frede Donskov, Cora N. Sternberg
Mean (95% CI) of simulated pazopanib steady state exposure metrics on day 28 by dose in historical (black) and PROTECT (red) populations under fasted state
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e1923b0b4dd89fdeaae8f11d366f85
https://doi.org/10.1158/1078-0432.22464765.v1
https://doi.org/10.1158/1078-0432.22464765.v1
Autor:
Guillaume Baneyx, William M. Sallas, Hequn Yin, Neva Coello, Jerry Nedelman, Penny Zhu, Francois Pierre Combes
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 45:707-719
Everolimus is approved in Europe and in the USA for the adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalization, are associated with tuberous sclerosis complex. The obj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9eefff448a114a8ee517d2ed275daff
https://doi.org/10.1007/s10928-018-9600-2
https://doi.org/10.1007/s10928-018-9600-2
Autor:
Hiya Banerjee, Naomi B. Haas, Christian Doehn, Robert J. Motzer, Paul Russo, Frede Donskov, Mohamed Elmeliegy, Guillaume Baneyx, Cora N. Sternberg, Paola Aimone
Publikováno v:
Sternberg, C, Donskov, F, Haas, N B, Doehn, C, Russo, P, Elmeliegy, M A, Baneyx, G, Banerjee, H, Aimone, P & Motzer, R J 2018, ' Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma ', Clinical Cancer Research, vol. 24, no. 13, pp. 3005-3013 . https://doi.org/10.1158/1078-0432.CCR-17-2652
Purpose: PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between pazopanib exposure (Ctrough) and efficacy and safety was evaluated. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8af2d37456f00c25e1851ed72ab12a57
https://doi.org/10.1158/1078-0432.ccr-17-2652
https://doi.org/10.1158/1078-0432.ccr-17-2652
Autor:
Janna Sand-Dejmek, Andrés Cervantes, Shuqi Chen, Miguel Martín, Jincheng Wu, Anne-Laure Marchal, Guillaume Baneyx, Jennifer Marie Mataraza, David Quinn
Publikováno v:
Cancer Research. 81:LB061-LB061
Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is a humanized monoclonal antibody against CSF-1. L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c7fbab2e05652abf32bf669f1b7d905
https://doi.org/10.1158/1538-7445.am2021-lb061
https://doi.org/10.1158/1538-7445.am2021-lb061